Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Sponsor
Peng Liu
Study ID
NCT05940064
Phase
PHASE2
Status
Unknown

Conditions

  • Diffuse Large B Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanubrutinib, Polatuzumab Vedotin, Rituximab — DRUG
    Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1

Study Details

This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in elderly patients with treatment-naive diffuse large B-cell lymphoma.

Key Dates

Start date
Jul 20, 2023
Status verified
Jul 2023
Primary completion
Jul 20, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Elderly Treatment-naive Diffuse Large B-cell Lymphoma
    Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Primary Outcome Measure

ORR at the end of the 6th treatment cycle [ Time Frame: about six months from the start of ZPR ]

Central Contacts

Related Studies